These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 38502780)
81. Discovery and Characterization of the First Nonpeptide Antagonists for the Relaxin-3/RXFP3 System. Gay EA; Guan D; Van Voorhies K; Vasukuttan V; Mathews KM; Besheer J; Jin C J Med Chem; 2022 Jun; 65(11):7959-7974. PubMed ID: 35594150 [TBL] [Abstract][Full Text] [Related]
82. Real-time examination of cAMP activity at relaxin family peptide receptors using a BRET-based biosensor. Valkovic AL; Leckey MB; Whitehead AR; Hossain MA; Inoue A; Kocan M; Bathgate RAD Pharmacol Res Perspect; 2018 Oct; 6(5):e00432. PubMed ID: 30263124 [TBL] [Abstract][Full Text] [Related]
83. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. Chow BS; Chew EG; Zhao C; Bathgate RA; Hewitson TD; Samuel CS PLoS One; 2012; 7(8):e42714. PubMed ID: 22936987 [TBL] [Abstract][Full Text] [Related]
84. Receptors for relaxin family peptides. Bathgate RA; Ivell R; Sanborn BM; Sherwood OD; Summers RJ Ann N Y Acad Sci; 2005 May; 1041():61-76. PubMed ID: 15956688 [TBL] [Abstract][Full Text] [Related]
85. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity. Pini A; Shemesh R; Samuel CS; Bathgate RA; Zauberman A; Hermesh C; Wool A; Bani D; Rotman G J Pharmacol Exp Ther; 2010 Dec; 335(3):589-99. PubMed ID: 20826567 [TBL] [Abstract][Full Text] [Related]
86. Alterations of relaxin and its receptor system components in experimental diabetic cardiomyopathy rats. Zhang X; Pan L; Yang K; Fu Y; Liu Y; Chen W; Ma X; Yin X Cell Tissue Res; 2017 Nov; 370(2):297-304. PubMed ID: 28776188 [TBL] [Abstract][Full Text] [Related]
87. International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Bathgate RA; Ivell R; Sanborn BM; Sherwood OD; Summers RJ Pharmacol Rev; 2006 Mar; 58(1):7-31. PubMed ID: 16507880 [TBL] [Abstract][Full Text] [Related]
88. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1. Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528 [No Abstract] [Full Text] [Related]
89. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells. Grampp S; Goppelt-Struebe M Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103 [TBL] [Abstract][Full Text] [Related]
90. Partial agonist activity of R3(BΔ23-27)R/I5 at RXFP3--investigation of in vivo and in vitro pharmacology. Kristensson L; Mayer G; Ploj K; Wetterlund M; Arlbrandt S; Björquist A; Wissing BM; Castaldo M; Larsson N Eur J Pharmacol; 2015 Jan; 747():123-31. PubMed ID: 25496752 [TBL] [Abstract][Full Text] [Related]
91. Synthesis of fluorescent analogs of relaxin family peptides and their preliminary in vitro and in vivo characterization. Chan LJ; Smith CM; Chua BE; Lin F; Bathgate RA; Separovic F; Gundlach AL; Hossain MA; Wade JD Front Chem; 2013; 1():30. PubMed ID: 24790958 [TBL] [Abstract][Full Text] [Related]
93. Exploring electrostatic interactions of relaxin family peptide receptor 3 and 4 with ligands using a NanoBiT-based binding assay. Wang JH; Nie WH; Shao XX; Li HZ; Hu MJ; Liu YL; Xu ZG; Guo ZY Biochim Biophys Acta Biomembr; 2019 Apr; 1861(4):776-786. PubMed ID: 30684458 [TBL] [Abstract][Full Text] [Related]
95. Identification of the N-linked glycosylation sites of the human relaxin receptor and effect of glycosylation on receptor function. Yan Y; Scott DJ; Wilkinson TN; Ji J; Tregear GW; Bathgate RA Biochemistry; 2008 Jul; 47(26):6953-68. PubMed ID: 18533687 [TBL] [Abstract][Full Text] [Related]
96. The minimal active structure of human relaxin-2. Hossain MA; Rosengren KJ; Samuel CS; Shabanpoor F; Chan LJ; Bathgate RA; Wade JD J Biol Chem; 2011 Oct; 286(43):37555-65. PubMed ID: 21878627 [TBL] [Abstract][Full Text] [Related]
97. Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design. D'Ercole A; Nistri S; Pacini L; Carotenuto A; Santoro F; Papini AM; Bathgate RAD; Bani D; Rovero P Front Pharmacol; 2022; 13():942178. PubMed ID: 36034864 [TBL] [Abstract][Full Text] [Related]
98. Relaxin-induced changes in renal function and RXFP1 receptor expression in the female rat. Bogzil AH; Ashton N Ann N Y Acad Sci; 2009 Apr; 1160():313-6. PubMed ID: 19416210 [TBL] [Abstract][Full Text] [Related]
99. Relaxin increased blood pressure and sympathetic activity in paraventricular nucleus of hypertensive rats via enhancing oxidative stress. Bian R; Gong J; Li J; Li P Peptides; 2021 Jul; 141():170550. PubMed ID: 33839220 [TBL] [Abstract][Full Text] [Related]
100. Sex-steroid regulation of relaxin receptor isoforms (RXFP1 & RXFP2) expression in the patellar tendon and lateral collateral ligament of female WKY rats. Dehghan F; Muniandy S; Yusof A; Salleh N Int J Med Sci; 2014; 11(2):180-91. PubMed ID: 24465164 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]